Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116610 · ClinicalTrials.gov registry record · Phase 2
Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer
A Phase 2 study, sponsored by Poniard Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00116610 is a Phase 2 study that has completed, run by Poniard Pharmaceuticals. The registered enrollment target is 75 participants.
The verdict
NCT00116610, a Phase 2 study, has completed, sponsored by Poniard Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a Phase II research study that is designed for patients who have small cell lung cancer (SCLC) that is no longer responding to treatment. Patients will receive picoplatin, a new platinum-based agent that is currently under investigation, in 21-day cycles.
Interventions
- DRUG picoplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116610
The ClinicalTrials.gov registry entry for NCT00116610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Poniard Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which picoplatin is the first listed.
NCT00116610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116610 about?
NCT00116610 is a clinical study titled "Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer". This is a Phase II research study that is designed for patients who have small cell lung cancer (SCLC) that is no longer responding to treatment. Patients will receive picoplatin, a new platinum-based agent that is currently under investigation, in 21-day cycles.
What is the current status of trial NCT00116610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2005-06. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00116610?
The interventions under investigation include: picoplatin (DRUG).
Who is sponsoring clinical trial NCT00116610?
This trial is sponsored by Poniard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.